Making Better CAR-T Cells to Fight Lymphoma
This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.
Original patent title: “Chimeric antigen receptor T cell therapy”
This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects. Granted to Kite Pharma in 2026 with 15 claims, and it is expected to expire in 2041.
Coverage
What does this patent actually cover?
The patent claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → a method for making an anti-CD19 Chimeric Antigen Receptor (CAR)-T cell immunotherapy product that works better and has fewer severe side effects for Non-Hodgkin's Lymphoma (NHL) patients. It involves taking a patient's T cells and, during the manufacturing process, specifically increasing or maximizing the percentage of "naïve" CD4+ and CD8+ T cells, identified by the CD45RA+ CCR7+ markers (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1). This optimized product must contain at least 20x10^6 of these specific naïve T cells, adjusted for the patient's tumor size (Claim 1). For example, a patient with relapsed/refractory large B-cell lymphoma (Claim 3) would receive a CAR-T infusion engineered with a higher proportion of these specific T cells, aiming for a more lasting response and less severe cytokine release syndrome or neurological issues (Claim 1).
The gap
What does this patent NOT cover?
- Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover CAR-T cell manufacturing methods that do not ensure at least 20x10^6 of these specific naïve T cells in the final product (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover CAR-T cell therapies targeting antigens other than CD19 (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover CAR-T cell therapies for cancers other than Non-Hodgkin's Lymphoma, advanced-stage indolent NHL, large B-cell lymphoma, or Mantle Cell Lymphoma (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 3).
- Does not cover methods of simply administering CAR-T cells without a specific manufacturing step to enrich for naïve T cells.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever bit is recognizing that not all T cells are equally effective in CAR-T therapy, and that enriching for a specific "naïve" T cell phenotype (CD45RA+ CCR7+) during manufacturing can lead to both better, more lasting cancer responses and fewer severe side effects like cytokine release syndrome.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Yescarta (axicabtagene ciloleucel)
Tecartus (brexucabtagene autoleucel)
Other anti-CD19 CAR-T cell therapies
Personalized cancer immunotherapies
Why it matters
The bigger picture
Chimeric Antigen Receptor (CAR)-T cell therapy is a powerful, personalized treatment for certain blood cancers, but it can have severe side effects and not all patients respond durably. This patent addresses these challenges by proposing a manufacturing method to create a more effective and safer CAR-T product. By focusing on specific T cell types, it aims to improve patient outcomes, making this advanced therapy more widely applicable and tolerable.
Filed
February 20, 2021
Granted
May 19, 2026
Market context
Who's building on this
Companies in this space
Kite Pharma, a Gilead company and the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more → of this patent, is a leader in CAR-T cell therapy, with approved products like Yescarta and Tecartus. Other major players like Novartis (Kymriah), Bristol Myers Squibb (Breyanzi, Abecma), and Johnson & Johnson are also actively developing and refining CAR-T cell manufacturing and therapies. These companies are continually researching ways to improve the efficacy and safety of cell-based immunotherapies.
Market impact
This patent aims to refine existing CAR-T cell therapies, which have already created a new category of personalized cancer treatment. If successful, it could lead to next-generation CAR-T products with better safety profiles and higher long-term success rates, potentially expanding the eligible patient population and further solidifying CAR-T's role in oncology. It could also influence manufacturing standards for future cell therapies, driving innovation in how these complex treatments are prepared and delivered to patients.
Claim 1 — Plain English
What this patent covers
The patent claims a method for making an anti-CD19 Chimeric Antigen Receptor (CAR)-T cell immunotherapy product that works better and has fewer severe side effects for Non-Hodgkin's Lymphoma (NHL) patients. It involves taking a patient's T cells and, during the manufacturing process, specifically increasing or maximizing the percentage of "naïve" CD4+ and CD8+ T cells, identified by the CD45RA+ CCR7+ markers (Claim 1). This optimized product must contain at least 20x10^6 of these specific naïve T cells, adjusted for the patient's tumor size (Claim 1). For example, a patient with relapsed/refractory large B-cell lymphoma (Claim 3) would receive a CAR-T infusion engineered with a higher proportion of these specific T cells, aiming for a more lasting response and less severe cytokine release syndrome or neurological issues (Claim 1).
The clever bit
The clever bit is recognizing that not all T cells are equally effective in CAR-T therapy, and that enriching for a specific "naïve" T cell phenotype (CD45RA+ CCR7+) during manufacturing can lead to both better, more lasting cancer responses and fewer severe side effects like cytokine release syndrome.
What it does not cover
- Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).
- Does not cover CAR-T cell manufacturing methods that do not ensure at least 20x10^6 of these specific naïve T cells in the final product (Claim 1).
- Does not cover CAR-T cell therapies targeting antigens other than CD19 (Claim 1).
- Does not cover CAR-T cell therapies for cancers other than Non-Hodgkin's Lymphoma, advanced-stage indolent NHL, large B-cell lymphoma, or Mantle Cell Lymphoma (Claim 3).
- Does not cover methods of simply administering CAR-T cells without a specific manufacturing step to enrich for naïve T cells.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
10/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$54K – $173K
Midpoint $108K · 14.2 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
15 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Rossi, J., Kim, J. J., Bot, A., GO, W., Plaks, V., & CHOU, S. (2026). Making Better CAR-T Cells to Fight Lymphoma (U.S. Patent No. 12,630,603). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12630603/chimeric-antigen-receptor-t-cell-therapy-12630603
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12630603"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 12600775 · 2026 · Kite Pharma
Treating a Specific Lymphoma with Modified T Cells
US 9328156 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Attack Cancer
US 9481728 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Fight CD19 Cancers
US 12564648 · 2026 · Washington University in St. Louis
Gene Editing T-Cells to Fight CD7 Blood Cancers
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Making Better CAR-T Cells to Fight Lymphoma cover?
This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.
Who owns patent US 12630603?
Kite Pharma owns this patent, granted in 2026.
When does this patent expire?
This patent is expected to expire on February 20, 2041, when the invention enters the public domain.
What problem does this patent solve?
Chimeric Antigen Receptor (CAR)-T cell therapy is a powerful, personalized treatment for certain blood cancers, but it can have severe side effects and not all patients respond durably. This patent addresses these challenges by proposing a manufacturing method to create a more effective and safer CAR-T product. By focusing on specific T cell types, it aims to improve patient outcomes, making this advanced therapy more widely applicable and tolerable.
What does this patent NOT cover?
Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).
Same assignee
More from Kite Pharma
Patent monitoring




